Lessons from the SWITCH trial: changing glucocorticoids in the management of metastatic castration-resistant prostate cancer (mCRPC)

Abiraterone acetate plus prednisone is a standard treatment option for mCRPC. The phase II SWITCH trial showed that further prostate-specific antigen (PSA) responses can be obtained in a subset of patients when prednisone was switched to dexamethasone at progression. Here, we discuss the potential u...

Descripción completa

Detalles Bibliográficos
Autores principales: Teo, Min Yuen, Scher, Howard I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6219496/
https://www.ncbi.nlm.nih.gov/pubmed/30344307
http://dx.doi.org/10.1038/s41416-018-0239-y
_version_ 1783368664282562560
author Teo, Min Yuen
Scher, Howard I.
author_facet Teo, Min Yuen
Scher, Howard I.
author_sort Teo, Min Yuen
collection PubMed
description Abiraterone acetate plus prednisone is a standard treatment option for mCRPC. The phase II SWITCH trial showed that further prostate-specific antigen (PSA) responses can be obtained in a subset of patients when prednisone was switched to dexamethasone at progression. Here, we discuss the potential underlying mechanisms, including the activation of glucocorticoid receptors (GR) in progressive mCRPC and the implications for clinical practice.
format Online
Article
Text
id pubmed-6219496
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-62194962019-10-22 Lessons from the SWITCH trial: changing glucocorticoids in the management of metastatic castration-resistant prostate cancer (mCRPC) Teo, Min Yuen Scher, Howard I. Br J Cancer Editorial Abiraterone acetate plus prednisone is a standard treatment option for mCRPC. The phase II SWITCH trial showed that further prostate-specific antigen (PSA) responses can be obtained in a subset of patients when prednisone was switched to dexamethasone at progression. Here, we discuss the potential underlying mechanisms, including the activation of glucocorticoid receptors (GR) in progressive mCRPC and the implications for clinical practice. Nature Publishing Group UK 2018-10-22 2018-10-30 /pmc/articles/PMC6219496/ /pubmed/30344307 http://dx.doi.org/10.1038/s41416-018-0239-y Text en © Cancer Research UK 2018 https://creativecommons.org/licenses/by/4.0/Note: This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).
spellingShingle Editorial
Teo, Min Yuen
Scher, Howard I.
Lessons from the SWITCH trial: changing glucocorticoids in the management of metastatic castration-resistant prostate cancer (mCRPC)
title Lessons from the SWITCH trial: changing glucocorticoids in the management of metastatic castration-resistant prostate cancer (mCRPC)
title_full Lessons from the SWITCH trial: changing glucocorticoids in the management of metastatic castration-resistant prostate cancer (mCRPC)
title_fullStr Lessons from the SWITCH trial: changing glucocorticoids in the management of metastatic castration-resistant prostate cancer (mCRPC)
title_full_unstemmed Lessons from the SWITCH trial: changing glucocorticoids in the management of metastatic castration-resistant prostate cancer (mCRPC)
title_short Lessons from the SWITCH trial: changing glucocorticoids in the management of metastatic castration-resistant prostate cancer (mCRPC)
title_sort lessons from the switch trial: changing glucocorticoids in the management of metastatic castration-resistant prostate cancer (mcrpc)
topic Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6219496/
https://www.ncbi.nlm.nih.gov/pubmed/30344307
http://dx.doi.org/10.1038/s41416-018-0239-y
work_keys_str_mv AT teominyuen lessonsfromtheswitchtrialchangingglucocorticoidsinthemanagementofmetastaticcastrationresistantprostatecancermcrpc
AT scherhowardi lessonsfromtheswitchtrialchangingglucocorticoidsinthemanagementofmetastaticcastrationresistantprostatecancermcrpc

Ejemplares similares